{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=T-Cell+Lymphoma", "query": { "condition": "T-Cell Lymphoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1547, "total_pages": 155, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=T-Cell+Lymphoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T19:04:41.331Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00104923", "title": "Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Cancer Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 29, "start_date": "2005-02", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-07-19", "last_synced_at": "2026-06-10T19:04:41.331Z", "location_count": 4, "location_summary": "Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104923" }, { "nct_id": "NCT00424242", "title": "Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Metastatic Cancer", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous Condition", "Secondary Myelofibrosis", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 15, "start_date": "2007-01", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2021-09-08", "last_synced_at": "2026-06-10T19:04:41.331Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00424242" }, { "nct_id": "NCT05944562", "title": "Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mycosis Fungoides", "Sezary Syndrome", "Mycosis Fungoides/Sezary Syndrome" ], "interventions": [ { "name": "Tulmimetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-01-09", "completion_date": "2029-01-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-06-10T19:04:41.331Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05944562" }, { "nct_id": "NCT03872180", "title": "Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CCND1 Positive", "Mantle Cell Lymphoma", "t(11;14) Positive" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2019-04-11", "completion_date": "2026-04-30", "has_results": true, "last_update_posted_date": "2025-08-06", "last_synced_at": "2026-06-10T19:04:41.331Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Johns Creek, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Johns Creek", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03872180" }, { "nct_id": "NCT01087333", "title": "Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hairy Cell Leukemia (HCL)", "Chronic Lymphocytic Leukemia (CLL)", "Non-Hodgkins Lymphoma (NHL)", "Cutaneous T Cell Lymphoma (CTCL)", "Adult T Cell Lymphoma (ATL)" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1263, "start_date": "2010-03-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-10T19:04:41.331Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087333" }, { "nct_id": "NCT00324597", "title": "AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Lymphoma", "Lymphoproliferative Disorder", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "motesanib diphosphate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2005-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-17", "last_synced_at": "2026-06-10T19:04:41.331Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324597" }, { "nct_id": "NCT00421213", "title": "Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Neoplasms", "Bone Marrow Neoplasms", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Darinaparsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2006-12", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2012-07-19", "last_synced_at": "2026-06-10T19:04:41.331Z", "location_count": 6, "location_summary": "Miami, Florida • Chicago, Illinois • Bethesda, Maryland + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Fargo", "state": "North Dakota" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00421213" }, { "nct_id": "NCT00058617", "title": "Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epstein-Barr Virus-Related Hodgkin Lymphoma", "Epstein-Barr Virus-Related Non-Hodgkin Lymphoma", "EBV Positive Plasma Cell Neoplasm" ], "interventions": [ { "name": "Injection of EBV Specific CTLs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 13, "start_date": "1996-01", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-06-10T19:04:41.331Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058617" }, { "nct_id": "NCT01943682", "title": "Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Burkitt Lymphoma", "Diffuse Large Cell Lymphoma", "Gray Zone Lymphoma", "Lymphoblastic Lymphoma", "Anaplastic Large Cell Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "CPX-351", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Months to 30 Years" }, "enrollment_count": 27, "start_date": "2013-09", "completion_date": "2019-04", "has_results": false, "last_update_posted_date": "2020-11-09", "last_synced_at": "2026-06-10T19:04:41.331Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01943682" }, { "nct_id": "NCT01634217", "title": "Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Non-Hodgkin Lymphoma", "Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Multiple Myeloma", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "iTreg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 16, "start_date": "2013-11-08", "completion_date": "2018-12-01", "has_results": false, "last_update_posted_date": "2019-01-18", "last_synced_at": "2026-06-10T19:04:41.331Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01634217" } ] }